Serono is investing in Genmab antibody

August 2005
Chemical Market Reporter;8/22/2005, Vol. 268 Issue 6, p7
Trade Publication
Reports on European biotechnology company Serono's plan to invest in Genmab AS as part of an agreement in which Serono gets exclusive worldwide rights to develop and commercialize Genmab's oncology monoclonal antibody, HuMax-CD4 (zanolimumab). Terms of the agreement; Development of the HuMax-CD4 for the treatment of cutaneous and noncutaneous T-cell lymphomas; Amount to be gained by Genmab from the deal.


Related Articles

  • Serono secures T-cell blocker. Odriscoll, Cath // European Chemical News;5/9/2005, Vol. 82 Issue 2146, p24 

    Reports on the rights to develop and commercialise the monoclonal antibody product HuMax-TAC granted to biotechnology company Serono by the drug manufacturer Genmab in Denmark. Information on the monoclonal antibody product; Views of Timothy Wells, head of research at Serono, on the HuMax-TAC;...

  • Genmab reaches milestones in cancer collaboration with GSK.  // PharmaWatch: Cancer;Mar2008, Vol. 7 Issue 3, p4 

    The article reports that Genmab AS has reached the second and third development milestones for ofatumumab monoclonal antibody under its collaboration with GlaxoSmithKline. The second milestone payment of the collaboration is triggered by the treatment of patients in diffuse large B-cell...

  • GENMAB/IMMUNEX TO DISCOVER AND DEVELOP CANCER ANTIBODY.  // Worldwide Biotech;Nov2001, Vol. 13 Issue 11, p6 

    Presents information on a collaborative agreement of Genmab A/S with Immunex Corporation to discover and develop an antibody against lymphoma as of November 2001.

  • Clinic Roundup.  // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p8 

    The article reports that Genmab A/S submitted a protocol amendment for its ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL).

  • Genmab Shares Rise on Ofatumumab CLL Data. Sheridan, Cormac // BioWorld International;12/10/2008, Vol. 13 Issue 50, p1 

    The article reports that shares of Genmab A/S gained as much as 13 percent following the release of additional clinical data of its brand of ofatumumab, Arzera. Its anti-CD20 monoclonal antibody is now undergoing Phase III trials in patients with refractory chronic lymphocyte leukemia (CLL). The...

  • Genmab Shares Slide as It Shelves Zalutumumab. Sheridan, Cormac // BioWorld Today;6/27/2011, Vol. 22 Issue 123, p2 

    The article reports an 11 percent drop of shares in Genmab A/S in June 2011 caused by news on the failure of the company to secure a deal for its epidermal growth factor receptor (EGFR) inhibitor zalutumumab. The company also decided to terminate the program after it missed the primary endpoint...

  • Genmab Lands $1.1B Cancer Deal with 'Perfect Partner' J&J. Moran, Nuala // BioWorld Today;8/31/2012, Vol. 23 Issue 170, p1 

    The article reports on a worldwide commercialization deal signed by Genmab A/S with Janssen Biotech Inc. for the anti-CD38 monoclonal antibody daratumumab. The terms of the deal include Jansen paying for all costs of developing the drug and its participation in a development plan involving 10 or...

  • Genmab's Arzerra Hits RA Goal But Doubts Arise About its Future. Sheridan, Cormac // BioWorld Today;7/31/2009, Vol. 20 Issue 146, p1 

    The article reports on the increase in share price of Genmab A/S following the release of preliminary data from a Phase III trial of the anti-CD20 monoclonal antibody Arzerra (ofatumumab) in rheumatoid arthritis (RA) patients refractory to methotrexate therapy in July 2009. Information on the...

  • Blockbuster MAbs Fueling Big Deals. Flanagan, Nina // Pharma DD: Tracking Discovery & Development;Jan/Feb2007, Vol. 2 Issue 1, p40 

    The article reports on mergers and acquisitions within the pharmaceutical industry caused by the success of monoclonal antibodies (mAb)-based therapeutics. One is the $2.1 billion development and marketing deal signed by GSK with Genmab for its HuMax-CD20 antibody. Another trend in the mAb...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics